Edition:
United States

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

41.93USD
19 Oct 2018
Change (% chg)

$-0.33 (-0.78%)
Prev Close
$42.26
Open
$42.42
Day's High
$42.50
Day's Low
$40.74
Volume
17,349
Avg. Vol
26,916
52-wk High
$68.91
52-wk Low
$25.58

Chart for

About

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for... (more)

Overall

Beta: --
Market Cap(Mil.): $715.93
Shares Outstanding(Mil.): 15.85
Dividend: --
Yield (%): --

Financials

  URGN.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -2.75 -- --
ROI: -44.55 1.96 12.83
ROE: -44.55 1.12 14.95

Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.

Jun 21 2018

INTERVIEW-Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel, June 21 Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.

Jun 21 2018

BRIEF-Urogen Pharma Announces Positive Interim Results From Pivotal Phase 3 Olympus Trial Of UGN-101

* UROGEN PHARMA ANNOUNCES POSITIVE INTERIM RESULTS FROM PIVOTAL PHASE 3 OLYMPUS TRIAL OF UGN-101 (MITOGEL™) FOR NON-SURGICAL TREATMENT OF UPPER TRACT UROTHELIAL CANCER (UTUC)

May 21 2018

BRIEF-UroGen Pharma Reports Q1 Loss Per Share Of $0.88

* UROGEN PHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

May 15 2018

Earnings vs. Estimates